key: cord-0974364-uuj9kyav
authors: Chen, Qijian; Wang, Lingling; Li, Chang; Hu, Weihua; Fan, Yameng; Chen, Zaishu; Wu, Longlong; Lu, Zhanjin; Ye, Jianfang; Chen, Shiyan; Tong, Junlu; Ruan, Liemin; Mei, Jin; Lu, Hongyun
title: Chronic Cardio‐Metabolic Disease Increases the Risk of Worse Outcomes Among Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, and Real‐World Study
date: 2021-06-05
journal: J Am Heart Assoc
DOI: 10.1161/jaha.120.018451
sha: 88c6e55da03c24f646a7abab9d954cac8dcc08e2
doc_id: 974364
cord_uid: uuj9kyav

BACKGROUND: Although chronic cardio‐metabolic disease is a common comorbidity among patients with COVID‐19, its effects on the clinical characteristics and outcome are not well known. METHODS AND RESULTS: This study aimed to explore the association between underlying cardio‐metabolic disease and mortality with COVID‐19 among hospitalized patients. This multicenter, retrospective, and real‐world study was conducted from January 22, 2020 to March 25, 2020 in China. Data between patients with and without 5 main cardio‐metabolic diseases including hypertension, diabetes mellitus, coronary heart disease, cerebrovascular disease, and hyperlipidemia were compared. A total of 1303 hospitalized patients were included in the final analysis. Of them, 520 patients (39.9%) had cardio‐metabolic disease. Compared with patients without cardio‐metabolic disease, more patients with cardio‐metabolic disease had COVID‐related complications including acute respiratory distress syndrome (9.81% versus 3.32%; P<0.001), acute kidney injury (4.23% versus 1.40%; P=0.001), secondary infection (13.9% versus 9.8%; P=0.026), hypoproteinemia (12.1% versus 5.75%; P<0.001), and coagulopathy (19.4% versus 10.3%; P<0.001), had higher incidences of the severe type of COVID‐19 (32.9% versus 16.7%; P<0.001), more were admitted to the intensive care unit (11.7% versus 7.92%; P=0.021), and required mechanical ventilation (9.8% versus 4.3%; P<0.001). When the number of the patients' cardio‐metabolic diseases was 0, 1, and >2, the mortality was 4.2%, 11.1%, and 19.8%, respectively. The multivariable‐adjusted hazard ratio of mortality among patients with cardio‐metabolic disease was 1.80 (95% CI, 1.17–2.77). CONCLUSIONS: Cardio‐metabolic disease was a common condition among hospitalized patients with COVID‐19, and it was associated with higher risks of in‐hospital mortality.

The data that support the findings of this study are available from the corresponding author upon reasonable request. This multicenter, retrospective, observational, and real-world study was done in hospitalized patients (≥18 years old) who were physician-diagnosed with COVID-19 according to the criteria published by the World Health Organization. 7 Patients who had a definite outcome (dead or discharged) between January 22, 2020 and March 25, 2020 were enrolled in the present analysis. We collected data of 1402 patients with laboratory-confirmed SARS-CoV-2 infection in 6 designated tertiary hospitals in Hubei province, with 3 in Wuhan city and 3 in cities outside Wuhan (Table S1 ). This study protocol of case series was approved by each local institutional ethics committees. Written informed consent was waived by the Ethics Commission of the designated hospital for emerging infectious diseases.

We reviewed clinical electronic medical records, nursing records, laboratory measurements, and radiological examinations for all patients with laboratoryconfirmed COVID-19 infection by using standard data collection forms. The research team of experienced clinicians analyzed patients' medical records. A trained teams of physicians and researchers independently entered and cross-checked the data in a computerized database. If the data were missing from the records or clarification was needed, we obtained data by direct communication with attending doctors and other healthcare providers. All data were checked by 2 physicians and a third researcher to adjudicate any difference in interpretation between the 2 primary reviewers.

We collected data on age, sex, exposure history, chronic medical histories (chronic cardiac disease, cerebrovascular disease, diabetes mellitus, hypertension, hyperlipidemia, and current smoking),

What Is New?

• The clinical characteristics and outcome of hospitalized patients with COVID-19 with chronic cardio-metabolic disease are described in this article. • In this multicenter, retrospective, and real-world study, chronic cardio-metabolic disease was a common condition (39.9%) among 1303 hospitalized patients with COVID-19 in China, and was significantly associated with higher risks of in-hospital mortality.

What Are the Clinical Implications?

• Patients with COVID-19 with underlying cardio-metabolic disease have a higher risk of in-hospital mortality, face a greater risk of developing severe outcomes, and need more medical attention and intervention. • This study will help clinicians to identify high-risk patients.

MERS Middle East respiratory syndrome symptoms from onset to hospital admission (fever, cough, sputum production, dyspnea, hemoptysis, fatigue, headache, and nausea or vomiting, diarrhea), and vital signs (temperature, pulse, respiratory rate, blood pressure, and blood oxygen saturation). Routine blood examinations included complete blood count, coagulation profile, serum biochemical tests (including renal and liver function, fasting glucose, lactate dehydrogenase, and electrolytes) and myocardial enzymes (creatine kinase, hypersensitive troponin I), inflammation biomarkers (CRP [C-reactive protein] and procalcitonin), chest computerized tomography scan data, complications, and treatments (oxygen therapy, antiviral agents, antibacterial agents, corticosteroid, and intravenous immunoglobulin). Length of hospital stay, intensive care unit (ICU) admission, mechanical ventilation therapy, and mortality were also collected.

Cardio-metabolic disease was defined as patients who had 1 or more doctor-diagnosed diseases including hypertension, diabetes mellitus, coronary heart disease, cerebrovascular disease, and dyslipidemia. All of the above diseases were ascertained from hospital admission records and discharge registries. Hypertension was defined according to the National Heart Lung and Blood Institute criteria, 8 or by use of antihypertensive drugs. Diabetes mellitus was defined by a history of diabetes mellitus, high blood glucose levels (fasting glucose ≥7 mmol/L or hemoglobin A1c ≥6.5%) at laboratory measurements or treatment of diabetes mellitus. Coronary heart disease was defined as a history of coronary heart disease, included myocardial infarction and congestive heart failure. Cerebrovascular disease was defined as a history of cerebrovascular disease. 9 Transient ischemic attacks were excluded from this definition. Acute kidney injury was doctor-diagnosed according to the Kidney Disease: Improving Global Outcomes clinical practice guidelines. 10 Acute respiratory distress syndrome (ARDS) was physician-diagnosed according to the Berlin Definition. 11 Acute cardiac injury was defined according to the criteria mentioned in the literature. 12 Coagulopathy was defined as a 3-second extension of prothrombin time or a 5-second extension of activated partial thromboplastin time. 13 Hypoproteinemia was defined as blood albumin of <30 g/L.

The primary outcome was in-hospital mortality after admission. Secondary outcomes were incidences of COVID-19-related complications, including ARDS, acute cardiac injury, acute kidney injury, secondary infection, shock, hypoproteinemia, and coagulopathy; the proportion of severe outcomes, such as ICU admission, mechanical ventilation therapy, classification of disease severity, and length of hospital stays. According to the Chinese management guideline for COVID-19 (version 7.0), the illness severity of COVID-19 was divided into 4 groups (mild, general, severe, and critical). 14 We divided the patients into 2 groups: the nonsevere group (mild and general types) and the severe group (severe and critical types).

Differences in demographic, history of diseases, clinical symptoms, laboratory measurements, radiological examinations, treatment, and clinical outcome between patients with and without cardio-metabolic disease were tested using the independent sample t test or Mann-Whitney test for continuous variables and Pearson χ 2 or the Fisher exact test for categorical variables. Cox proportional hazards models were used to estimate hazard ratios (HRs) of mortality among patients with and without cardio-metabolic disease (or each cardio-metabolic disease). Logistic regression models were used to estimate odds ratios (ORs) of secondary outcomes, including the ICU admission and the rate of severe type of COVID-19, among patients with and without cardio-metabolic disease (or each cardio-metabolic disease). All analyses were adjusted for age and sex (Model 1); and then for smoking and systolic blood pressure (Model 2); and further for hypertension, diabetes mellitus, hyperlipidemia, coronary heart disease, and cerebrovascular disease, other than the variable for stratification (Model 3); the CRP, white blood cell count, d-dimer, lactate dehydrogenase, and procalcitonin were added in Model 4. The Kaplan-Meier plot was performed to compare 40-day survival probability for those with and without diabetes mellitus by log-rank test. All statistical analyses were performed with SPSS statistics version 23.0 for Windows software package (IBM). Two-sided P<0.05 was considered statistically significant.

By March 25, 2020, clinical data were collected on 1402 adult patients. The final sample comprised 1303 patients after excluding 55 patients physiciandiagnosed without positive SARS-CoV-2 data (clinical diagnosis cases), and 44 patients with incomplete data on main medical information or outcome. Figure 1 shows a flowchart for patient recruitment. The median age was 56 years (range, 42-66 years), and 658 cases (50.5%) were male.

General characteristics of the study population at baseline are given in Table 1 P<0.001) as compared with those who remained free of cardio-metabolic disease. There were no significant differences in the gastrointestinal symptoms such as nausea, vomiting, or diarrhea. The laboratory parameters among patients with COVID-19 with or without cardio-metabolic disease are also presented in Table 2 . Patients with cardiometabolic disease had higher median levels of leukocyte counts (5.91 versus 5.2×10 9 per L), neutrophil count (4.19 versus 3. than patients without cardio-metabolic disease. Compared with patients without cardio-metabolic disease, patients with cardio-metabolic disease had a higher proportion of bilateral involvement (75.4% versus 63.0%) and interstitial abnormalities (2.7% versus 0.4%) assessed by chest computerized tomography images.

All patients were given aggressive treatment according to their conditions and expert suggestions and treatment guidelines at that time. Table 3 shows the treatments and outcomes among patients with COVID-19 with and without cardio-metabolic disease. Compared with patients without cardio-metabolic disease, more patients with cardio-metabolic disease had COVID-19related complications including ARDS (9.81% versus 3.32%; P<0.001), acute kidney injury (4.23% versus 1.40%; P=0.001), secondary infection (13.9% versus 9.83%; P=0.026), hypoproteinemia (12.1% versus 5.75%; P<0.001), and coagulopathy (19.4% versus 10.3%; P<0.001), had higher incidences of the severe type of COVID-19 (32.9% versus 16.7%; P<0.001), were admitted to ICU (11.7% versus 7.92%; P=0.021), required more mechanical ventilation (included noninvasive mechanical ventilation and invasive mechanical ventilation, 9.81% versus 4.34%; P<0.001), and renal replacement (2.50% versus 0.13%, P<0.001). There were no significant differences on the antiviral therapy, antibiotic therapy, and use of corticosteroid and intravenous immunoglobin treatment between patients with and without cardio-metabolic disease. The ORs of secondary outcomes, including the ICU admission, the rate of severe type of COVID-19, and mechanical ventilation therapy among patients with and without cardiometabolic disease (or each cardio-metabolic disease) are respectively shown in Tables S2 through S4.

In order to compare the risk factor for severity and death of COVID-19, all the cases were divided into severe and nonsevere groups, and survivor and nonsurvivor; we found that there were more patients with cardiometabolic disease in the nonsurvivor (69.4% versus 37.2%; P<0.001) ( Figure 2A ) and severe groups (56.6% versus 34.9%; P<0.001) ( Figure 2B ). The number of patients with cardio-metabolic disease is associated with the mortality of COVID-19. When the number of the patients' cardio-metabolic diseases was 0, 1, and ≥2, the mortality was 4.2%, 11.1%, and 19.8%, respectively. The multivariable-adjusted (age, sex, smoking, and systolic blood pressure) OR of mortality among patients with cardio-metabolic disease, compared with those without it, was 1.86 (95% CI, 1.17-2.97). The survival curve of patients with and without cardio-metabolic disease with COVID-19 is shown in Figure 3 . Among the patients with cardio-metabolic disease, 75 of 520 (14.42%) patients died, while of those who were without cardio-metabolic disease, 33 of 783 (4.21%) died. Patients with COVID-19 with cardio-metabolic disease appeared to have an elevated risk of death compared with patients without cardio-metabolic disease. The multivariable-adjusted HR of in-hospital mortality was also higher in patients with hypertension (HR, 1.86; 95% CI, 1.23-2.82) and cerebrovascular disease (HR, 2.78; 95% CI, 1.57-4.93) compared with patients without hypertension and cerebrovascular disease, respectively (Table 4 ). Furthermore in the adjusted model 4, which added the coagulation and inflammation-related biomarkers such as CRP, white blood cell count, d-dimer, lactate dehydrogenase, and procalcitonin, there was no statistically significant difference in HR between different cardio-metabolic diseases.

Coronavirus is one of the main pathogens of respiratory infection. Two highly pathogenic viruses, SARS-CoV and MERS-CoV, respectively, resulted in outbreaks of 15 SARS-CoV and MERS-CoV are associated with cardio-metabolic disease. In a Hong Kong retrospective cohort study, diabetes mellitus was found to be an important risk factor for adverse outcome. 16 Another retrospective study reported that hypertension was one of the frequent underlying conditions associated with death among MERS-CoV-infected patients. 17 Although SARS-CoV and MERS-CoV have the same origin, the relationships between cardio-metabolic disease and the different outcomes among patients with SARS-CoV-2 infection remain unclear. Several recent studies have found that patients with COVID-19 have high morbidity of cardio-metabolic disease. In 1 study of 99 cases with COVID-19 in China, 50 (51%) patients had chronic diseases including cardiovascular and cerebrovascular diseases (40%), and endocrine system disease (13%). 4 In the other study of 5700 patients in New York City, the most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes mellitus (1808; 33.8%). 6 The present study indicated that 39.9% of patients with COVID-19 had cardio-metabolic disease including patients with more than 2 diseases (197 of 520 [37.9%]), 27.32% patients had hypertension, and 15.35% patients had diabetes mellitus. Race, selection of population, and study design are all important factors contributing to the heterogeneity of prevalence estimates. One recent study by Guo et al reported that diabetes mellitus was a risk factor for rapid progression and poor prognosis of COVID-19. 18 A meta-analysis including 6263 COVID-19 cases has identified that preexisting chronic conditions such as hypertension, cardiovascular disease, chronic kidney disease, and diabetes mellitus were strongly associated with an increased risk of developing severe COVID-19. 19 However, very few studies have assessed the direct association between cardio-metabolic disease and several important outcomes including in-hospital mortality, COVID-related complications, ICU admission, and mechanical ventilation among patients with COVID-19. The present study found that patients with COVID-19 with cardiometabolic disease were more common in COVIDrelated complications including ARDS, acute heart injury, acute kidney injury, secondary infection, hypoproteinemia, and coagulopathy, were more admitted to the ICU, required more mechanical ventilation therapy, and had a higher risk of mortality compared with patients without cardio-metabolic disease. Moreover, our study demonstrated that patients with COVID-19 with hypertension and cerebrovascular disease may be independent risk factors for all-cause mortality in patients with COVID-19. All these data suggest that patients with SARS-CoV-2 infection who had underlying cardio-metabolic disease should be hospitalized earlier and get more medical intervention.

Several studies of COVID-19 have proposed that SARS-CoV-2 induces a cytokine storm in the body, generates a series of immune responses, and causes changes in peripheral white blood cells and immune cells such as lymphocytes. 4, 20 In the present Data are expressed as n (%) or mean (interquartile range). P values were calculated by independent sample t test, Mann-Whitney U test, Pearson χ 2 , or Fisher exact test, as appropriate. APTT indicates activated partial thromboplastin time; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and TG, triglyceride. Table 2 . Continued study, we found that patients with COVID-19 with cardio-metabolic disease had higher levels of several inflammation-related biomarkers such as CRP, procalcitonin, the absolute count of neutrophils and white blood cells, and lactate dehydrogenase compared with patients without cardio-metabolic disease. These data provide further evidence for the presence of cytokine storm that can further contribute to complications. For the inflammatory storm, several studies indicated that d-dimer was significantly higher in severe cases than in moderate cases with COVID-19. 21 Our study found that patients with cardio-metabolic disease had higher levels of ddimer and higher incidence of coagulopathy than patients without cardio-metabolic disease. According to our results, we found that the coagulation and inflammation-related biomarkers had a strong relationship with COVID-19 related death, influenced the relationship between cardio-metabolic diseases and the COVID-19 related death. So we speculated that the relationship between cardio-metabolic diseases and COVID-19-related death may be modified by coagulation and inflammation-related biomarkers. Guo et al hypothesized that hypoxia-induced molecules can activate thrombin directly, and the activation of monocyte-macrophages would also secrete a mass of tissue factors and activate the exogenous coagulation pathway, which lead to an overall hypercoagulable state or even disseminated intravascular coagulation. 18 Recent studies have confirmed that SARS-CoV-2 uses the same cell entry receptor (angiotensin-converting enzyme II) as SARS-CoV, which does not use other coronavirus receptors, such as aminopeptidase N, and dipeptidyl peptidase 4. 22 This leads to the activation of CD4+ T cells, which proliferate and differentiate into Th1 cells that secrete proinflammatory cytokines such as IL-6, interferon, and granulocytemacrophage colony-stimulating factor; this can eventually develop into a cytokine storm, which can cause progression to ARDS, multiple organ failure, and even death. 23 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the 2 types of renin-angiotensin-aldosterone system inhibitors widely used for treating hypertension. This may be one of the underlying mechanisms why patients with COVID-19 with hypertension or cerebrovascular disease had more rates of worse outcomes. But there were also studies that did not support the significant interference of hypertension on COVID-19 lethality. 24 Previously published data have shown that use of renin-angiotensin-aldosterone system inhibitors by patients with COVID-19 was associated with a reduced risk of all-cause mortality. 25, 26 Therefore, some researchers have hypothesized that high angiotensin-converting enzyme II expression could be deleterious during the contamination phase, whereas the high angiotensin-converting enzyme II expression could, in contrast, be beneficial during the inflammation phase and may possibly prevent organ injury in COVID-19. 27 An earlier report of 72 314 cases from the Chinese Center for Disease Control and Prevention showed that the overall case-fatality rate was 2.3% (1023 deaths among 44 672 confirmed cases). 28 A research study of 1099 patients with COVID-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in China reported that the morality was 1.4%. 5 In the present study the mortality is 8.29%, higher than the reports mentioned above. We proposed that our data were from mortality in hospital patients in Hubei province; the patients had more severe disease than those in the temporary treatment centers (as Fangcang hospitals), and the patients out of Hubei province, subsequently the mortality was higher. Moreover, our study demonstrated that patients with COVID-19 with hypertension and cerebrovascular disease also had an increased risk of death, and the more cardiometabolic diseases the patients had, the higher the morbidity patients with COVID-19 presented.

The study also has some limitations. First, because of the retrospective, multiple-center, and real-world study design, some information, such as patients' height, weight, several laboratory items (such as glycosylated hemoglobin) and lipid-lowering and other cardio-preventive treatments were not available for all patients. We can only draw correlations rather than causal relationships between cardio-metabolic disease and COVID-19. Second, study samples were only from Hubei province, China; thus more studies in other regions or even other countries might provide a more comprehensive understanding of COVID-19. For the data analysis, there was no adjustment for multiple testing and an inflated type-1 error was made. However, this study is one of the largest retrospective, multicenter, and real-world studies among patients with COVID-19. Compared with the study in New York City, 16 all the cases of the present study had a definite end point, and we all have more than 1 month follow-up of these cases. The relatively rich clinical data and numerous events also strengthen the results. The conclusion will help clinicians to identify high-risk patients.

We found that cardio-metabolic disease was a common condition among hospitalized patients with COVID-19, and was associated with higher risks of in-hospital mortality. Hypertension and cerebrovascular disease may be 2 important diseases associated with in-hospital death after adjusting for age, sex, and smoking. More intensive attention should be paid to those patients with COVID-19 who had underlying cardio-metabolic disease. Model 1 adjusted for age and sex; model 2 adjusted for age, sex, smoking, and systolic blood pressure; model 3 adjusted for age, sex, smoking, systolic blood pressure, hypertension, diabetes mellitus, hyperlipidemia, coronary heart disease, and cerebrovascular disease, other than the variable for stratification; model 4 adjusted for age, sex, smoking, systolic blood pressure, C-reactive protein, white blood cell count, d-dimer, lactate dehydrogenase, and procalcitonin. Cox proportional hazards models were used to estimate hazard ratios of mortality among patients with and without cardio-metabolic disease (or each cardiometabolic disease).

A novel coronavirus from patients with pneumonia in China

Available at: HYPERLINK "sps:urlprefix::https

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of coronavirus disease 2019 in China

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Available at: HYPERLINK "sps:urlprefix::https" https:// www.who.int/publi catio ns-detai l/clini cal-manag ement -of-sever e-acute -respi rator y-infec tion-when-novel -coron aviru s-(ncov)-infec tion-issuspe cted

Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

The role of cardiovascular risk factors and stroke in familial Alzheimer disease

KDIGO clinical practice guidelines for acute kidney injury

Acute respiratory distress syndrome: the Berlin definition

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

National Health Commission of the People's Republic of China

COVID-19 pandemic, corona viruses, and diabetes mellitus

Secular trends in all-cause and causespecific mortality rates in people with diabetes in Hong Kong

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Diabetes is a risk factor for the progression and prognosis of COVID-19

Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and immunologic features in severe and moderate coronavirus disease 2019

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients

Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension

Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Inhibitors of the renin-angiotensin-aldosterone system and Covid-19

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

We thank Professor Gang Hu (Louisiana State University, Pennington Biomedical Research Center, Baton Rouge, LA) for guidance in study design and interpretation of results, and review of the manuscript. The authors are grateful for all healthcare workers involved in the diagnosis and treatment of patients in Hubei Province. 

None.

Tables S1-S4